Experience
Joshua A. Youngkin is a civil litigator who handles plaintiff’s general liability claims, personal injury/auto accidents, insurance coverage disputes, employment discrimination, real estate and business litigation. Previously, while working for two large insurance defense firms (2020 – 2023), he defended businesses in claims for products liability, commercial liability, and general liability. While staff attorney at a plaintiff’s boutique firm (2015 – 2020), and also while at a well-known corporate defense firm, he developed expertise in the use of legal tech to power discovery in document heavy multidistrict federal antitrust cases that challenged core business practices of Fortune 100 companies in the pharmaceutical and investment banking industries.

Prior to civil litigation (2011 – 2014), he was a public policy attorney and lobbyist for a think tank. His work centered on improving science education in the nation’s public schools and advising statehouses on adoption of Common Core State Standards, Next Generation Science Standards, and Academic Freedom legislation, while also defending in court the freedom of speech and conscience in higher education. Before law school (2007 – 2010), he was for nearly seven years (2001 – 2007) a network engineer at high tech startup that used satellites to provide broadband connectivity to businesses and militaries all over the world. Mr. Youngkin enjoys working with experts and learning new things.

Representative Matters

ISDAfix Securities Manipulation Settlement: Worked with a team of attorneys to establish by documentary evidence the commission of various interconnected anticompetitive acts between January 1, 2006, and January 31, 2014 (amidst the Great Recession), by which seventeen financial institutions, including Goldman Sachs Group, Inc., manipulated the market for ISDAfix Instruments (mainly interest rate swap variations) in violation of Section 1 of the Sherman Act, 15 U.S.C. § 1. Resolution of the class action involved payment of nearly $500MM by the defendants to the settlement class.

EpiPen Price Gouging Settlement: Worked with a team of attorneys to establish by documentary evidence that drugmaker Mylan (now Viatris, Inc.) engaged in an unlawful pay-for-delay settlement with drugmaker Teva, resulting in delayed release of a generic EpiPen, thus allowing Mylan to raise EpiPen’s price without competition. Resolution of the class action involved payment of $264MM by Mylan and $345MM by Pfizer to the settlement class.

Remicade Rebate Trap Settlement: Worked with a team of attorneys to establish by documentary evidence that Jannsen Pharmaceuticals (subsidiary of Johnson & Johnson) set a rebate trap via exclusionary contracts with prescribers, insurers, and PBMs favoring Remicade that forced Pfizer’s biosimilar Inflectra (generic for Remicade) into an unsustainable business model to the ultimate detriment of patients/consumers. Resolution of the class action involved payment of $25MM by Jannsen to the settlement class.

Education/Admissions
He obtained his Juris Doctor (J.D.) from the University of San Diego School of Law and his B.A. in International Business from San Diego State University. In law school, he completed externships with the San Diego Superior Court, for judges Dahlquist and Elias, served as President of the Federalist Society, USD Law Chapter, served as Executive Editor of the Journal of Contemporary Legal Issues, served as Research Assistant to Prof. Roy L. Brooks, served as Research Assistant to Prof. Michael Rappaport. After law school, he published a law review article on the teaching style and content of academic Stanley Fish. He is admitted to practice in California, the state of Washington, and the United States District Court for the Central District of California.